SOST and postmenopausal osteoporosis: The study results demonstrate that anti-sclerostin antibodies can be used to treat postmenopausal osteoporosis.<h4>Systematic review registration</h4>https://www.crd.york.ac.uk/PROSPERO/recorddashboard, identifier CRD420251103597.